{"denoms":[{"counts":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"89"},{"groupId":"BG003","value":"57"},{"groupId":"BG004","value":"464"}],"units":"Participants"}],"groups":[{"description":"2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.","id":"BG000","title":"Group 2 (Chemotherapy, Surgery)"},{"description":"4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.","id":"BG001","title":"Group 3 (Chemotherapy, Surgery)"},{"description":"8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients \\< 12 months of age with stg 3, 4, or 4S disease who achieve a very good PR (VGPR) to chemo (with the exception of resolution of skin or liver metastases in stage 4S patients) proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.","id":"BG002","title":"Group 4 (Chemotherapy, Surgery, Antineoplastic Therapy)"},{"description":"The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.\n\nSurgery: With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.","id":"BG003","title":"Non-intermediate Risk Enrolled on Intermediate Risk Trial"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"89"},{"groupId":"BG003","value":"57"},{"groupId":"BG004","value":"464"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1.47","value":"1.23"},{"groupId":"BG001","spread":".89","value":".74"},{"groupId":"BG002","spread":".36","value":".60"},{"groupId":"BG003","spread":"1.83","value":"1.51"},{"groupId":"BG004","spread":"1.26","value":"0.99"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"49"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"217"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"31"},{"groupId":"BG004","value":"247"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"57"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"74"},{"groupId":"BG003","value":"49"},{"groupId":"BG004","value":"382"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"25"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"19"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"8"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"52"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"59"},{"groupId":"BG003","value":"40"},{"groupId":"BG004","value":"324"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"59"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"}]}],"title":"New Zealand"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"37"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"153"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"78"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"412"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"12"}]}],"title":"Australia"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}